GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Return-on-Tangible-Asset

Stoke Therapeutics (Stoke Therapeutics) Return-on-Tangible-Asset : -46.06% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Stoke Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-107.83 Mil. Stoke Therapeutics's average total tangible assets for the quarter that ended in Dec. 2023 was $234.12 Mil. Therefore, Stoke Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -46.06%.

The historical rank and industry rank for Stoke Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

STOK' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -227.88   Med: -31.97   Max: -19.22
Current: -41.45

During the past 7 years, Stoke Therapeutics's highest Return-on-Tangible-Asset was -19.22%. The lowest was -227.88%. And the median was -31.97%.

STOK's Return-on-Tangible-Asset is ranked worse than
50.9% of 1556 companies
in the Biotechnology industry
Industry Median: -40.005 vs STOK: -41.45

Stoke Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Stoke Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Return-on-Tangible-Asset Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -19.22 -19.84 -31.97 -40.84 -43.23

Stoke Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.46 -33.53 -45.52 -39.52 -46.06

Competitive Comparison of Stoke Therapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Stoke Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stoke Therapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Stoke Therapeutics's Return-on-Tangible-Asset falls into.



Stoke Therapeutics Return-on-Tangible-Asset Calculation

Stoke Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-104.699/( (256.067+228.342)/ 2 )
=-104.699/242.2045
=-43.23 %

Stoke Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-107.832/( (239.889+228.342)/ 2 )
=-107.832/234.1155
=-46.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Stoke Therapeutics  (NAS:STOK) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Stoke Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics (Stoke Therapeutics) Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.
Executives
Barry Ticho officer: Chief Medical Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Ian F Smith director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jonathan Allan officer: General Counsel & Corp Sec C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Huw M. Nash officer: COO & CBO C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Atp Life Science Ventures, L.p. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd. 10 percent owner 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Skorpios Trust 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd 10 percent owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd 10 percent owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau officer: EVP Research & Preclinical Dev C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin director 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Stephen J Tulipano officer: CFO C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Arthur Tzianabos director C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kaye Edward M. Md director, officer: CEO 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011

Stoke Therapeutics (Stoke Therapeutics) Headlines

From GuruFocus